April 19, 2017: Immunogen’s stock popped 13% today on an upgrade from Leerink Partners. Leerink Partners raised Immunogen to an Outperform rating, from Market Perform, and set a price target of $8. Leerink Partners is upgrading Immunogen based on their higher level of conviction on lead asset mirvetuximab soravtansine providing an attractive risk/reward in context (Read More….)
GBT exploded into position #1 gaining 31% last week. Nomura initiated coverage of GBT with a Buy rating and a price target of $50. Let’s go ahead and book profits on Monday if you haven’t already. Remember folks, sell into strength and don’t wait for me to issue a sell signal before cashing out and (Read More….)
OREX continues to be our dominant stock pick up a whopping +80% since profiled on GuerillaStockTrading.com
The biggest new gainer this last week was PLX which rocketed higher after it received FDA Orphan Drug Designation for CTP-656 for the treatment of Cystic Fibrosis.
Another big climber was CGIX after it launched its entry into comprehensive (Read More….)
Orexigen Therapeutics continues to be the top performing stock since profiled on GuerillaStockTrading.com. Orexigen Therapeutics is up an incredible +74.59%.
Here are the top performing stocks on GuerillaStockTrading.com for the week ending January 13, 2017.
OREX = +74.59% XGTI = +46.26% LPTH = +25.71% EXAS = +24.64% RNVA = +22.22% IMGN = +20.59% OPGN (Read More….)